Vaidehi Dave
YOU?
Author Swipe
View article: RETROSPECTIVE EVALUATION OF THE IMPACT OF KNEE OSTEOARTHRITIS SEVERITY ON TREATMENT OUTCOMES: A LONGITUDINAL STUDY
RETROSPECTIVE EVALUATION OF THE IMPACT OF KNEE OSTEOARTHRITIS SEVERITY ON TREATMENT OUTCOMES: A LONGITUDINAL STUDY Open
Background: Knee osteoarthritis (OA) affects approximately 528 million people worldwide, representing a significant healthcare burden with variable treatment outcomes based on disease severity. Understanding the relationship between severi…
View article: From clinical trials to informing clinical decision-making: a review of patient-reported outcomes in nononcology medicines approved by the European Medicines Agency (2018–2022)
From clinical trials to informing clinical decision-making: a review of patient-reported outcomes in nononcology medicines approved by the European Medicines Agency (2018–2022) Open
Introduction Information about a medicine published in the Summary of Product Characteristics (SmPC) and the product’s package leaflet by the European Medicines Agency (EMA) is key to communicate its value to prescribers and patients. The …
View article: Comparing Outcomes of Telerehabilitation vs. In-Person Therapy in Knee Osteoarthritis Management
Comparing Outcomes of Telerehabilitation vs. In-Person Therapy in Knee Osteoarthritis Management Open
Background: This study aimed to assess the effectiveness of telerehabilitation and in-person therapy in treating osteoarthritis (OA) of the knee in terms of pain management, functional improvement, and patient satisfaction. Method: A rando…
View article: 1437 Analysis by treatment period and liver function in EMERALD-1: a phase 3 study of durvalumab ± bevacizumab + TACE in participants with embolization-eligible unresectable hepatocellular carcinoma
1437 Analysis by treatment period and liver function in EMERALD-1: a phase 3 study of durvalumab ± bevacizumab + TACE in participants with embolization-eligible unresectable hepatocellular carcinoma Open
View article: Avelumab First-Line Maintenance for Locally Advanced or Metastatic Urothelial Carcinoma: Results From the Real-World US PATRIOT-II Study
Avelumab First-Line Maintenance for Locally Advanced or Metastatic Urothelial Carcinoma: Results From the Real-World US PATRIOT-II Study Open
These results align with the JAVELIN Bladder 100 clinical trial and other real-world studies, supporting avelumab 1LM use in patients with la/mUC without progression following 1L PBC.
View article: Knowledge, Attitudes, and Practices of European Healthcare Professionals towards Hepatitis A and Hepatitis B Vaccination in at-Risk Adults
Knowledge, Attitudes, and Practices of European Healthcare Professionals towards Hepatitis A and Hepatitis B Vaccination in at-Risk Adults Open
Despite the occurrence of several hepatitis A (hepA) and hepatitis B (hepB) outbreaks in Europe in the last few decades, not all European countries have implemented hepA and hepB vaccinations in their national immunization programs, especi…
View article: HSD73 First- and Second-Line Treatment Patterns in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Chart Review Study in Three Countries
HSD73 First- and Second-Line Treatment Patterns in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Chart Review Study in Three Countries Open
View article: Health-related quality of life (QoL) in patients with advanced melanoma receiving immunotherapies in real-world clinical practice settings
Health-related quality of life (QoL) in patients with advanced melanoma receiving immunotherapies in real-world clinical practice settings Open
Background Pembrolizumab (PEMBRO) and ipilimumab + nivolumab (IPI + NIVO) are approved advanced melanoma (AM) immunotherapies. To address limited health-related quality of life (QoL) real-world evidence with immunotherapies in AM, we compa…
View article: Hospitalization and emergency department utilization in patients with advanced melanoma receiving pembrolizumab versus ipilimumab plus nivolumab in US academic centers
Hospitalization and emergency department utilization in patients with advanced melanoma receiving pembrolizumab versus ipilimumab plus nivolumab in US academic centers Open
Background: Both pembrolizumab (PEMBRO) and ipilimumab + nivolumab (IPI + NIVO) are FDA-approved immunotherapy regimens for advanced melanoma (AM). Each regimen has different toxicity profiles potentially impacting healthcare resour…
View article: Factors Associated with Immunotherapy Selection in Patients with Advanced Melanoma
Factors Associated with Immunotherapy Selection in Patients with Advanced Melanoma Open
Patient factors are significantly associated with treatment selection in advanced melanoma. Outcomes comparisons should take this into consideration.